Abstract
Leukoreduction of blood products is a technique used to prevent leukocyte-induced transfusion reactions and is extensively used in human, but rarely in veterinary patients. The concentration of some coagulation proteins can be affected by the processing steps used for the preparation of leuko-reduced plasma units. In this study, we assessed the effect of leukoreduction on coagulation activity of canine plasma collected for transfusion. Ten plasma units, five obtained from non-leuko-reduced (non-LR) whole blood (WB) units and five from leuko-reduced (LR) WB units were evaluated. Prothrombin time (PT), activated partial thromboplastin time (aPTT), coagulation factor activities of factors (F) V, VIII, X, XI, and von Willebrand (vWF), fibrinogen and D-dimers content were assessed at collection (baseline value, D0) and after 7 days of frozen storage at −18 °C (D7). Compared to non-LR plasma units, LR units showed a statistically significant prolonged aPTT and reduced FXI activity. Filtration had no significant effect on the other factors and parameters evaluated. Filtration-dependent changes appear to have no impact on the therapeutic quality of plasma obtained from leuko-reduced whole blood, other than for FXI activity. Further studies on a larger sample size comparing the same unit before and after leukoreduction are needed to confirm these findings.
Highlights
Transfusion medicine has grown in recent decades and many canine patients today receive blood or blood components
Descriptive analyses relative to each coagulation parameter evaluated at D0 and D7 in LR and non-LR plasma units are reported in
We evaluated the effect of leukoreduction on hemostatic activity of plasma obtained from whole blood (WB) filtered by in-line polyester filters in the specific canine collection system
Summary
Transfusion medicine has grown in recent decades and many canine patients today receive blood or blood components. Plasma components, such as fresh frozen plasma (FFP), are used mainly to treat coagulopathies [1,2,3]. The plasma contains therapeutic levels of functional coagulation factors, transfusion of which is an essential component of treatment for many congenital and acquired coagulopathies [4,5]. Blood or plasma transfusions have the potential to cause severe and potentially lifethreatening reactions in recipients. Some of these reactions are due to the presence and activities of leukocytes. In human medicine in almost all countries, blood components undergo leukoreduction to prevent a number of leukocyte-induced transfusion reactions, such as febrile transfusion reactions [5]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call